Related Experiment Videos
[Bronchopulmonary aspergillosis (author's transl)]
Abstract:
Bronchopulmonary infections with Aspergillus give rise to three different pathological entities. Allergic bronchopulmonary aspergillosis, found in patients with an atopic predisposition, is marked by dyspnea of the asthmatic type associated with labile radiologically detectable infiltrates, blood hypereosinophilia, enhanced total IgE levels, specific IgG fractions, and positive immediate reactions to skin tests. The long-term risk is the development of proximal bronchiectasis. Dosage and duration of corticotherapy are function of eosinophilia and total IgE levels. Pathogenicity is similar to that of extrinsic allergic alveolitis, probably involving disturbances in immune complexes from a type I reaction. Intracavital pulmonary aspergillosis involves mycotic development within a cavity or a complicating parenchymatous lesion. Severe hemoptysis may occur. Medical treatment is ineffective, and radical surgery is necessary in patients able to support operative procedures, which vary as a function of the condition of the patient. Diffuse aspergillosis occurs in immunodeficient patients, usually during the acute phase of chemotherapy induction. Spread of the disease is either from the upper respiratory tract or through the blood as septicemia. A nosocomial origin is frequent. Diagnosis depends more on the presence of hyphae in tissue biopsy specimens than cultures or serological tests which are too unreliable. Treatment is with amphotericin B preferably associated with 5 fluorocytosin.
Insights
Aspergillus infections cause three lung conditions: allergic bronchopulmonary aspergillosis, intracavital aspergillosis, and diffuse aspergillosis. Diagnosis and treatment vary by type, impacting patient outcomes.
Area of Science:
- Pulmonology
- Infectious Diseases
- Mycology
Context:
- Bronchopulmonary infections caused by Aspergillus present distinct clinical and pathological entities.
- Understanding these conditions is crucial for accurate diagnosis and effective management in at-risk populations.
Purpose:
- To differentiate and describe the three main pathological entities of bronchopulmonary aspergillosis.
- To outline diagnostic criteria and treatment strategies for each form of Aspergillus lung infection.
Summary:
- Allergic bronchopulmonary aspergillosis (ABPA) occurs in atopic individuals, characterized by asthma-like symptoms, eosinophilia, elevated IgE, and potential bronchiectasis. Treatment involves corticosteroids guided by eosinophil and IgE levels.
- Intracavital pulmonary aspergillosis involves fungal growth within lung cavities, potentially causing severe hemoptysis, requiring surgical intervention as medical treatment is often ineffective.
- Diffuse aspergillosis affects immunodeficient patients, often hospital-acquired, with diagnosis relying on tissue biopsy. Treatment includes amphotericin B, potentially with 5-fluorocytosine.
Impact:
- Provides a clear framework for clinicians to diagnose and manage diverse Aspergillus-related lung diseases.
- Highlights the importance of tailored treatment approaches based on the specific Aspergillus pathology and patient immune status.
- Emphasizes diagnostic challenges and the need for reliable methods, particularly in immunocompromised individuals.